FindMyKOL

Stephen Selkirk, MD

Basic profile

Louis Stokes Cleveland VA Medical Center

ORCIDNone on fileNPIOn fileSign in to see identifiers
RegionGarfield Hts, OH · MidwestSpecialtyNeurologyFocusNeurology
Last active 2019FindMyKOL typeFindMyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPaymentsNone reportedNIH funding2017–2019Why? →

Stephen Selkirk is a Neurology physician affiliated with Louis Stokes Cleveland VA Medical Center. OpenAlex indexes 32 publications with 561 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
32publications

Publications indexed by OpenAlex. Counts exclude supporting files.

561citations

Citations across these publications.

12h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
1NIH grants · 2017–2019

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    83.7%
    Gabapentinoids14.5%
    Gabapentin71%Pregabalin26%Lyrica3%
    Part D<11 patients
    Other antiepileptics10.3%
    Levetiracetam47%Topiramate31%Lacosamide14%Briviact7%
    Part D<11 patients

    + 32 more classes in this area

  • Musculoskeletal

    6.2%
    Muscle Relaxant2.8%
    Cyclobenzaprine Hcl59%Methocarbamol33%Carisoprodol8%
    Part D<11 patients
    gamma-Aminobutyric Acid-ergic Agonist2%
    Baclofen100%
    Part D≥23 patients

    + 2 more classes in this area

  • Cardiovascular

    4.2%
    Beta blocker2.3%
    Propranolol Hcl53%Propranolol Hcl Er27%Metoprolol Succinate20%
    Part D<11 patients
    Statin1.2%
    Atorvastatin Calcium80%Rosuvastatin Calcium20%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2017–2019 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”